A dose-escalating toxicology study of the candidate biologic ELP-VEGF

Abstract Vascular Endothelial Growth Factor (VEGF), a key mediator of angiogenesis and vascular repair, is reduced in chronic ischemic renal diseases, leading to microvascular rarefaction and deterioration of renal function. We developed a chimeric fusion of human VEGF-A121 with the carrier protein...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jamarius P. Waller, Stephen P. Burke, Jason Engel, Alejandro R. Chade, Gene L. Bidwell
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8a90e0ab576444fa94b0057516ab228f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8a90e0ab576444fa94b0057516ab228f
record_format	dspace
spelling	oai:doaj.org-article:8a90e0ab576444fa94b0057516ab228f2021-12-02T17:04:59ZA dose-escalating toxicology study of the candidate biologic ELP-VEGF10.1038/s41598-021-85693-62045-2322https://doaj.org/article/8a90e0ab576444fa94b0057516ab228f2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85693-6https://doaj.org/toc/2045-2322Abstract Vascular Endothelial Growth Factor (VEGF), a key mediator of angiogenesis and vascular repair, is reduced in chronic ischemic renal diseases, leading to microvascular rarefaction and deterioration of renal function. We developed a chimeric fusion of human VEGF-A121 with the carrier protein Elastin-like Polypeptide (ELP-VEGF) to induce therapeutic angiogenesis via targeted renal VEGF therapy. We previously showed that ELP-VEGF improves renal vascular density, renal fibrosis, and renal function in swine models of chronic renal diseases. However, VEGF is a potent cytokine that induces angiogenesis and increases vascular permeability, which could cause undesired off-target effects or be deleterious in a patient with a solid tumor. Therefore, the current study aims to define the toxicological profile of ELP-VEGF and assess its risk for exacerbating tumor progression and vascularity using rodent models. A dose escalating toxicology assessment of ELP-VEGF was performed by administering a bolus intravenous injection at doses ranging from 0.1 to 200 mg/kg in Sprague Dawley (SD) rats. Blood pressure, body weight, and glomerular filtration rate (GFR) were quantified longitudinally, and terminal blood sampling and renal vascular density measurements were made 14 days after treatment. Additionally, the effects of a single administration of ELP-VEGF (0.1–10 mg/kg) on tumor growth rate, mass, and vascular density were examined in a mouse model of breast cancer. At doses up to 200 mg/kg, ELP-VEGF had no effect on body weight, caused no changes in plasma or urinary markers of renal injury, and did not induce renal fibrosis or other histopathological findings in SD rats. At the highest doses (100–200 mg/kg), ELP-VEGF caused an acute, transient hypotension (30 min), increased GFR, and reduced renal microvascular density 14 days after injection. In a mouse tumor model, ELP-VEGF did not affect tumor growth rate or tumor mass, but analysis of tumor vascular density by micro-computed tomography (μCT) revealed significant, dose dependent increases in tumor vascularity after ELP-VEGF administration. ELP-VEGF did not induce toxicity in the therapeutic dosing range, and doses one hundred times higher than the expected maximum therapeutic dose were needed to observe any adverse signs in rats. In breast tumor—bearing mice, ELP-VEGF therapy induced a dose-dependent increase in tumor vascularity, demanding caution for potential use in a patient suffering from kidney disease but with known or suspected malignancy.Jamarius P. WallerStephen P. BurkeJason EngelAlejandro R. ChadeGene L. BidwellNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jamarius P. Waller Stephen P. Burke Jason Engel Alejandro R. Chade Gene L. Bidwell A dose-escalating toxicology study of the candidate biologic ELP-VEGF
description	Abstract Vascular Endothelial Growth Factor (VEGF), a key mediator of angiogenesis and vascular repair, is reduced in chronic ischemic renal diseases, leading to microvascular rarefaction and deterioration of renal function. We developed a chimeric fusion of human VEGF-A121 with the carrier protein Elastin-like Polypeptide (ELP-VEGF) to induce therapeutic angiogenesis via targeted renal VEGF therapy. We previously showed that ELP-VEGF improves renal vascular density, renal fibrosis, and renal function in swine models of chronic renal diseases. However, VEGF is a potent cytokine that induces angiogenesis and increases vascular permeability, which could cause undesired off-target effects or be deleterious in a patient with a solid tumor. Therefore, the current study aims to define the toxicological profile of ELP-VEGF and assess its risk for exacerbating tumor progression and vascularity using rodent models. A dose escalating toxicology assessment of ELP-VEGF was performed by administering a bolus intravenous injection at doses ranging from 0.1 to 200 mg/kg in Sprague Dawley (SD) rats. Blood pressure, body weight, and glomerular filtration rate (GFR) were quantified longitudinally, and terminal blood sampling and renal vascular density measurements were made 14 days after treatment. Additionally, the effects of a single administration of ELP-VEGF (0.1–10 mg/kg) on tumor growth rate, mass, and vascular density were examined in a mouse model of breast cancer. At doses up to 200 mg/kg, ELP-VEGF had no effect on body weight, caused no changes in plasma or urinary markers of renal injury, and did not induce renal fibrosis or other histopathological findings in SD rats. At the highest doses (100–200 mg/kg), ELP-VEGF caused an acute, transient hypotension (30 min), increased GFR, and reduced renal microvascular density 14 days after injection. In a mouse tumor model, ELP-VEGF did not affect tumor growth rate or tumor mass, but analysis of tumor vascular density by micro-computed tomography (μCT) revealed significant, dose dependent increases in tumor vascularity after ELP-VEGF administration. ELP-VEGF did not induce toxicity in the therapeutic dosing range, and doses one hundred times higher than the expected maximum therapeutic dose were needed to observe any adverse signs in rats. In breast tumor—bearing mice, ELP-VEGF therapy induced a dose-dependent increase in tumor vascularity, demanding caution for potential use in a patient suffering from kidney disease but with known or suspected malignancy.
format	article
author	Jamarius P. Waller Stephen P. Burke Jason Engel Alejandro R. Chade Gene L. Bidwell
author_facet	Jamarius P. Waller Stephen P. Burke Jason Engel Alejandro R. Chade Gene L. Bidwell
author_sort	Jamarius P. Waller
title	A dose-escalating toxicology study of the candidate biologic ELP-VEGF
title_short	A dose-escalating toxicology study of the candidate biologic ELP-VEGF
title_full	A dose-escalating toxicology study of the candidate biologic ELP-VEGF
title_fullStr	A dose-escalating toxicology study of the candidate biologic ELP-VEGF
title_full_unstemmed	A dose-escalating toxicology study of the candidate biologic ELP-VEGF
title_sort	dose-escalating toxicology study of the candidate biologic elp-vegf
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8a90e0ab576444fa94b0057516ab228f
work_keys_str_mv	AT jamariuspwaller adoseescalatingtoxicologystudyofthecandidatebiologicelpvegf AT stephenpburke adoseescalatingtoxicologystudyofthecandidatebiologicelpvegf AT jasonengel adoseescalatingtoxicologystudyofthecandidatebiologicelpvegf AT alejandrorchade adoseescalatingtoxicologystudyofthecandidatebiologicelpvegf AT genelbidwell adoseescalatingtoxicologystudyofthecandidatebiologicelpvegf AT jamariuspwaller doseescalatingtoxicologystudyofthecandidatebiologicelpvegf AT stephenpburke doseescalatingtoxicologystudyofthecandidatebiologicelpvegf AT jasonengel doseescalatingtoxicologystudyofthecandidatebiologicelpvegf AT alejandrorchade doseescalatingtoxicologystudyofthecandidatebiologicelpvegf AT genelbidwell doseescalatingtoxicologystudyofthecandidatebiologicelpvegf
_version_	1718381801621159936

A dose-escalating toxicology study of the candidate biologic ELP-VEGF

Ejemplares similares